380893-73-2

Usage

Uses

Used in Research and Industrial Applications:
2-(Diethylphosphonylmethyl)-5-bromopyridine is used as a chemical intermediate for the synthesis of various compounds in research and industrial settings. Its specific uses may include the development of pharmaceuticals, agrochemicals, or other specialty chemicals, although further details about its applications are not readily available.
Used in Chemical Synthesis:
2-(Diethylphosphonylmethyl)-5-bromopyridine is used as a building block in the synthesis of complex organic molecules, particularly those that require the incorporation of phosphorus and bromine atoms. Its unique structure allows for the creation of novel compounds with potential applications in various fields.
Note: Due to the limited information provided, the specific uses, toxicological information, safety measures, and handling of 2-(Diethylphosphonylmethyl)-5-bromopyridine may require further research or consultation with experts in the field.

Upstream product

• 624-28-2 2,5-dibromopyridine 
• 88139-91-7 (5-bromopyridin-2-yl)methanol 
• 380893-61-8 (5-bromopyridin-2-yl)methyl methanesulfonate 
• 762-04-9 phosphonic acid diethyl ester 
• 122-52-1 triethyl phosphite 
• 168823-76-5 5-bromo-2-(chloromethyl)pyridine 
• 31181-64-3 5-bromo-2-methyl-pyridine-N-oxide 
• 3430-13-5 5-bromo-2-methylpyridine 

Downstream Products

• 1256607-08-5 Diethyl {[5-(2-methoxyphenyl)pyridin-2-yl]methyl}phosphonate 
• 1256607-06-3 Diethyl-[(5-phenylpyridin-2-yl)methyl]phosphonate 
• 380894-77-9 [5-(3-fluorophenyl)-pyridin-2-ylmethyl]-phosphonic acid diethyl ester 

Relevant academic research and scientific papers

Derivatives of hexahydrobenzofuranone useful for the treatment of (inter alia) auto-immune or inflammatory disorders

Heterocyclic-substituted compounds of formula (I) or a pharmaceutically acceptable salt thereof, are disclosed, wherein: Z is - (CH2)n-; (a); (b), wherein R 10 is absent; or, (c) wherein R 3 is absent; the single dotted line represents an optional double bond; the double dotted line represents an optional single bond; n is 0-2; Het is an optionally substituted mono-, bi- or tri-cyclic heteroaromatic group; B is -(CH 2 ) n3 -. wherein n 3 is 0-5, -CH 2 -O-, -CH 2 S-, -CH 2 -NR 6 -, -C(O)NR 6 -. -NR 6 C(O)-, (d), optionally substituted alkenyl or optionally substituted alkynyl; X is -O- or -NR 6 - when the double dotted line represents a single bond, or X is H, -OH or -NHR 20 when the bond is absent; Y is =O, =S, (H, H), (H, OH) or (H, C 1 -C 6 alkoxy) when the double dotted line represents a single bond or when the bond is absent, Y is =O, =NOR 17 (H, H). (H, OH), (H, SH), (H, C 1 -C 6 alkoxy) or (H, substituted-amino); R 22 and R 23 are independently -OH, -OC(O)R 30 , OC(O)NR 30 R 31 , or optionally substituted alkyl, alkenyl, alkynyl, heterocycloalkyl, aryl, cycloalkyl, cycloalkenyl, carbonyl, amino, alkoxy, alkenyloxy, alkynyloxy, heterocycloalkyloxy, cycloalkyloxy, or cycloalkenyloxy; or R 22 and R 10 , or R 23 and R 11 , can form a carbocyclic or heterocyclic ring; and the remaining variables are as described in the specification, Also disclosed are pharmaceutical compositions containing said compounds and their use as thrombin receptor antagonists and blinders to cannabinoid receptors.

Inhibition of 1-deoxy-d-xylulose-5-phosphate reductoisomerase by lipophilic phosphonates: SAR, QSAR, and crystallographic studies

1-Deoxy-d-xylulose-5-phosphate reductoisomerase (DXR) is a novel target for developing new antibacterial (including antituberculosis) and antimalaria drugs. Forty-one lipophilic phosphonates, representing a new class of DXR inhibitors, were synthesized, among which 5-phenylpyridin-2-ylmethylphosphonic acid possesses the most activity against E. coli DXR (EcDXR) with a K i of 420 nM. Structure-activity relationships (SAR) are discussed, which can be rationalized using our EcDXR:inhibitor structures, and a predictive quantitative SAR (QSAR) model is also developed. Since inhibition studies of DXR from Mycobacterium tuberculosis (MtDXR) have not been performed well, 48 EcDXR inhibitors with a broad chemical diversity were found, however, to generally exhibit considerably reduced activity against MtDXR. The crystal structure of a MtDXR:inhibitor complex reveals the flexible loop containing the residues 198-208 has no strong interactions with the 3,4-dichlorophenyl group of the inhibitor, representing a structural basis for the reduced activity. Overall, these results provide implications in the future design and development of potent DXR inhibitors.

Heterotricyclic himbacine analogs as potent, orally active thrombin receptor (protease activated receptor-1) antagonists

Pursuing our earlier efforts in the himbacine-based thrombin receptor antagonist area, we have synthesized a series of compounds that incorporate heteroatoms in the C-ring of the tricyclic motif. This effort has resulted in the identification of several p

EXO- AND DIASTEREO- SELECTIVE SYNTHESES OF HIMBACINE ANALOGS

The application discloses a novel process for the preparation of himbacine analogs useful as thrombin receptor antagonists. The process is based in part on the use of a base-promoted dynamic epimerization of a chiral nitro center. The chemistry taught her